On the recordMarch 29, 2023
PBMs benefit significantly from high list prices and have no incentive to choose lower-priced drugs to drive down patient costs.
Source
congress.govPBMs benefit significantly from high list prices and have no incentive to choose lower-priced drugs to drive down patient costs.
Menendez critiques PBMs for profiting from high drug prices.
Share
More from Bob Menendez Jr.
Thank you, Chairman. I want to join my colleagues in recognizing the loss of our colleague, Donald Payne, Jr.
I want to commend you and the dedicated public servants at DHS who stop more fentanyl and have arrested more drug traffickers in the last 2 fiscal years than the previous 5 combined.
We have talked a lot in our Cybersecurity Subcommittee, this Congress, about how to streamline reporting requirements to make sure they are effective.
Thank you for convening today's hearing on port cybersecurity and for allowing me to waive on.